New Lifetime High Reached By Five Prime Therapeutics (FPRX)
Trade-Ideas LLC identified
(
) as a new lifetime high candidate. In addition to specific proprietary factors, Trade-Ideas identified Five Prime Therapeutics as such a stock due to the following factors:
- FPRX has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $19.9 million.
- FPRX has traded 250,798 shares today.
- FPRX is trading at a new lifetime high.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in FPRX with the Ticky from Trade-Ideas. See the FREE profile for FPRX NOW at Trade-Ideas
More details on FPRX:
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. Currently there are 3 analysts that rate Five Prime Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.
The average volume for Five Prime Therapeutics has been 609,500 shares per day over the past 30 days. Five Prime has a market cap of $919.7 million and is part of the health care sector and drugs industry. Shares are up 33.8% year-to-date as of the close of trading on Friday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates Five Prime Therapeutics as a
. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and feeble growth in its earnings per share.
Highlights from the ratings report include:
- The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed compared to the Biotechnology industry average, but is greater than that of the S&P 500. The net income has decreased by 16.3% when compared to the same quarter one year ago, dropping from -$9.87 million to -$11.47 million.
- Net operating cash flow has significantly decreased to -$9.66 million or 180.16% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
- FIVE PRIME THERAPEUTICS INC's earnings per share improvement from the most recent quarter was slightly positive. This company has reported somewhat volatile earnings recently. We feel it is likely to report a decline in earnings in the coming year. During the past fiscal year, FIVE PRIME THERAPEUTICS INC reported poor results of -$1.80 versus -$1.33 in the prior year. For the next year, the market is expecting a contraction of 58.3% in earnings (-$2.85 versus -$1.80).
- The return on equity has improved slightly when compared to the same quarter one year prior. This can be construed as a modest strength in the organization. Compared to other companies in the Biotechnology industry and the overall market, FIVE PRIME THERAPEUTICS INC's return on equity significantly trails that of both the industry average and the S&P 500.
- FPRX has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 9.86, which clearly demonstrates the ability to cover short-term cash needs.
- You can view the full Five Prime Therapeutics Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.